VACCINE-CHALLENGED IMMUNE RESISTANCE TOWARD VIRUS A/CALIFORNIA/7/2009(H1N1)v IN IMMUNIZED PREGNANT WOMEN

We studied immune resistance efficiency of vaccination against influenza A/California/7/2009(H1N1)v in women at second trimester of physiological pregnancy in a blind, placebocontrolled study. The first group included thirty pregnant women who were injected by univalent subunit “MonoGrippol plus” va...

Full description

Saved in:
Bibliographic Details
Published inMedit͡s︡inskai͡a︡ immunologii͡a Vol. 14; no. 6; pp. 527 - 532
Main Authors Cherdantsev, A., Kostinov, M., Kuselman, А., Dagil, Y., Savis’ko, A. A.
Format Journal Article
LanguageEnglish
Published St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists 23.07.2014
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:We studied immune resistance efficiency of vaccination against influenza A/California/7/2009(H1N1)v in women at second trimester of physiological pregnancy in a blind, placebocontrolled study. The first group included thirty pregnant women who were injected by univalent subunit “MonoGrippol plus” vaccine. The second group consisted of thirty-seven pregnant women immunized by trivalent “Grippol plus” vaccine. Thirty-one pregnant women (III group) received placebo treatment. Non-pregnant women (IV group) were injected with “MonoGrippol plus”. We did not find any differences in clinical features of vacccine-challenged time period in pregnant women from groups I-III. Notably, sufficient numbers of women were found to be seroprotected 1 month post-vaccination (I group, 80.0% ; II group, 75.7% ; IVgroup, 80.6% ) with high levels seroconversion (I group, 46.6%; II group, 51.4%; IV group, 53.3%). Within 9-10 months after vaccination, a decreased seroprotection was revealed in II group of pregnant women. More stable specific immunity levels were detected for the groups immunized with univalent vaccine.Hence, the local subunit adjuvant “MonoGrippol plus” and “Grippol plus” vaccines were shown to exibit a high immune resistance efficiency profile and clinical safety, when used in pregnant women, thus presuming an extended application field for these biological drugs in public health service. State of pregnancy seems not to be a limiting condition for induction of specific immune resistance.
ISSN:1563-0625
2313-741X
DOI:10.15789/1563-0625-2012-6-527-532